Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients

NMTi payloadPositive

AI Analysis

Summary

Novartis has agreed to acquire Myricx Bio to expand its antibody-drug conjugate (ADC) portfolio with a novel NMTi payload technology for cancer treatment.

Importance:7/10

Sentiment:

0.60

M&Aantibody-drug conjugateoncologyADC technology

Related Companies

$NVS

Read the original article

Published by yahoo_finance on July 6, 2026 5:00 AM

Read Original